Itamar Medical Ltd.,  a medical device company, announced that in light of the growing evidence of the link between cardiovascular disease and obstructive sleep apnea (OSA), the company is expanding its business model by offering a comprehensive sleep apnea management solution to cardiologists, who seek to create a streamlined pathway for effective treatment. Itamar Medical markets the WatchPAT home sleep test and now offers a solution to manage the entire OSA care continuum for hospitals and clinics.

As part of its Total Sleep Solution (TSS) offering, Itamar will utilize its nationwide network of independent diagnostic testing facilities (IDTF), durable medical equipment (DME) service providers and sleep physicians.  Also utilized will be Itamar’s cloud-based IT platform solution, the CloudPAT, which encodes and transmits WatchPAT test results directly to physicians and their staff. The company believes this strategy further emphasizes the competitive advantages of the WatchPAT device.

“This expansion and our ability to provide comprehensive solutions for sleep apnea to cardiologists is centered around our unique and easy to use WatchPAT technology and firmly positions Itamar as an important player in a growing global market,” said Gilad Glick, CEO of Itamar Medical. “The Total Sleep Solution is a growing business opportunity; addressing a significant unmet need in the cardiology space, while contributing to improve the clinical outcomes of cardiovascular procedures. This approach allows us to offer more inclusive and convenient services to both patients and their physicians.”

Itamar Medical Ltd. is a publicly traded medical device company based in Israel’s Caesarea Industrial Park that develops non-invasive medical devices using the company’s proprietary platform technology, the PAT (Peripheral Arterial Tone) signal. The company currently markets the WatchPAT home sleep test for respiratory sleep disorder diagnosis, and the EndoPAT, the only device approved by the US FDA for testing endothelial (arterial) function and assessing the risk of coronary artery disease and other cardiovascular diseases.